Institutional members access full text with Ovid®

Share this article on:

New Drug Approved for Advanced Renal Cell Cancer

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: May 2012 - Volume 112 - Issue 5 - p 22,23
doi: 10.1097/01.NAJ.0000414312.49083.9b
Drug Watch
  • Axitinib (Inlyta), a tyrosine kinase inhibitor, has recently been approved for the treatment of advanced kidney cancer when other therapy hasn't been successful. Taken orally twice a day, axitinib prevents angiogenesis, tumor growth, and cancer progression.
  • Common adverse effects include diarrhea, hypertension, fatigue, anorexia, nausea, loss of voice, hand–foot syndrome, weight loss, vomiting, weakness, and constipation.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.